A5201: A PROSPECTIVE, OPEN-LABEL, PILOT TRIAL OF REGIMEN SIMPLIFICATION TO ATAZA

A5201：针对 ATAZA 方案简化的前瞻性、开放标签试点试验

• 批准号: 7604213
• 负责人: TIMOTHY J. WILKIN
• 金额: $ 0.03万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604213
• 关键词: Acquired Immunodeficiency Syndrome; Atazanavir; Clinical Treatment; Computer Retrieval of Information on Scientific Projects Database; End Point; Enrollment; Failure; Funding; Grant; Institution; Label; Patients; Pharmaceutical Preparations; Protease Inhibitor; Research; Research Personnel; Resources; Ritonavir; Source; Time; United States National Institutes of Health; pilot trial; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Regarding AIDS This study will enroll 33 patients who have been virologically suppressed on protease inhibitor and 2 NRTIs. In Step 1, patients will change their PI(s) to atazanavir/ritonavir. If they tolerate the drug change, they enter Step 2: they stop NRTIs and continue atazanavir/ritonavir alone. The primary endpoint is time to virologic failure through 24weeks.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 关于艾滋病 这项研究将纳入33名被病毒学抑制的蛋白酶抑制剂和2名NRTI的患者。在第一步中，患者将他们的PI(S)改为阿扎那韦/利托那韦。如果他们对药物变化耐受，他们进入步骤2：他们停止NRTI，并仅继续阿扎那韦/利托那韦。主要终点是病毒学故障持续24周的时间。